Diya Mohammad, MD
Pulmonary Disease · Medford, ORNPI 1427339738
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.9%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 71.4% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $4,794, 6.0 times the $797 reported in 2019.
Across 73 payments — averaging $116.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Pulmonx Corporation$943
- GSK$202
- Bayer$200
- Regeneron Healthcare Solutions, Inc.$172
- Sanofi-aventis U.S. LLC$162
- plus $759 from 19 others
What the payments were for
- Consulting fees$2002%
- Travel & lodging$3,99147%
- Food & beverage$1,64219%
- Education$2,67831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 23 | $6,074 |
| Pulmonx Corporation | 2 | $943 |
| GSK | 9 | $202 |
| Bayer | 1 | $200 |
| Regeneron Healthcare Solutions, Inc. | 4 | $172 |
| Sanofi-aventis U.S. LLC | 2 | $162 |
| Abiomed | 1 | $130 |
| Edwards Lifesciences | 1 | $97 |
| AstraZeneca | 4 | $68 |
| United Therapeutics Corporation | 3 | $63 |
| Insmed, Inc. | 3 | $50 |
| Sanofi | 3 | $42 |
| Merck | 2 | $41 |
| Baxter Healthcare | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Pfizer | 2 | $33 |
| Amgen | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Harmony Biosciences LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Electromed, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,658
- Pulmonx Endobronchial Valve EBV$943
- Adempas$200
- Impella$130
- DUPIXENT$115
How this compares
$8,512 in reported general payments places this provider in the 85th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 391 | $294,836 |
| Dupixent PenDupilumab | 61 | $231,171 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $145,647 |
| NucalaMepolizumab | 31 | $137,650 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $130,917 |
| Spiriva RespimatTiotropium Bromide | 137 | $98,241 |
| Breo ElliptaFluticasone/Vilanterol | 142 | $69,179 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $41,132 |
| Incruse ElliptaUmeclidinium Bromide | 70 | $24,407 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 140 | $22,064 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $16,344 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $13,549 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $13,150 |
| EliquisApixaban | 17 | $10,095 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 57 | $9,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $202 | $546,553687 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $17 | $130,91712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $68 | $48,24479 claims |
| PfizerEliquis | $33 | $10,09517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Medford
- Siva Rama Krishna MarriMedford$4K
- Stephen YauPortland$984K
- Jeremy FeldmanBend$456K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Matthew HegewaldBend$94K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.